SEARCH

SEARCH BY CITATION

References

  • 1
    Chen S, Law CS, Grigsby CL et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011; 124: 183847.
  • 2
    Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393408.
  • 3
    Touchberry CD, Green TM, Tchikrizov V et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013; 304: E86373.
  • 4
    Al Mheid I, Patel RS, Tangpricha V, Quyyumi AA. Vitamin D and cardiovascular disease: is the evidence solid? Eur Heart J2013; 34: 36918.
  • 5
    Tomson J, Emberson J, Hill M et al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Eur Heart J2013; 34: 136574.
  • 6
    Donate-Correa J, Muros de Fuentes M, Mora-Fernández C, Navarro-González JF. Pathophysiological implications of fibroblast growth factor-23 and klotho and their potential role as clinical biomarkers. Clin Chem 2013 (in press).
  • 7
    Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 268896.
  • 8
    Plischke M, Neuhold S, Adlbrecht C et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest 2012; 42: 64956.
  • 9
    Wesseling-Perry K. FGF23: is it ready for prime time? Clin Chem 2011; 57: 14767.
  • 10
    Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 24329.
  • 11
    Heine GH, Nangaku M, Fliser D. Calcium and phosphate impact cardiovascular risk. Eur Heart J 2013; 34: 111221.
  • 12
    Smith K, deFilippi C, Isakova T et al. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am J Kidney Dis 2013; 61: 6773.
  • 13
    Levin GP, Robinson-Cohen C, de Boer IH et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012; 308: 1898905.
  • 14
    Robinson-Cohen C, Hoofnagle AN, Ix JH et al. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA 2013; 310: 17988.
  • 15
    van Ballegooijen AJ, Snijder MB, Visser M et al. Vitamin D in relation to myocardial structure and function after eight years of follow-up: the Hoorn study. Ann Nutr Metab 2012; 60: 6977.
  • 16
    Ameri P, Canepa M, Milaneschi Y et al. Relationship between vitamin D status and left ventricular geometry in a healthy population: results from the Baltimore Longitudinal Study of Aging. J Intern Med 2013; 273: 25362.
  • 17
    Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 54651.
  • 18
    Ix JH, Katz R, Kestenbaum BR, de Boer IH et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: 2007.
  • 19
    Ärnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83: 1606.
  • 20
    Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH; on behalf of the NIGRAM Consortium. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 196878.
  • 21
    Gruson D, Lepoutre T, Ketelslegers JM, Cumps J, Ahn SA, Rousseau MF. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012; 37: 25862.
  • 22
    Mureddu GF, Agabiti N, Rizzello V et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail 2012; 14: 71829.
  • 23
    Masson S, Latini R, Mureddu GF et al. High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals. J Intern Med 2013; 273: 30617.
  • 24
    Zile MR, Tanaka R, Lindroth JR, Spinale F, Carabello BA, Mirsky I. Left ventricularvolume determined echocardiographically by assuming a constant left ventricularepicardial long-axis/short-axis dimension ratio throughout the cardiac cycle. J Am Coll Cardiol 1992; 20: 98693.
  • 25
    de Simone G, Devereux RB, Ganau A et al. Estimation of left ventricular chamber and stroke volume by limitedM-mode echocardiography and validation by two-dimensional and Doppler echocardiography. Am J Cardiol 1996; 78: 8017.
  • 26
    Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 35867.
  • 27
    Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79108.
  • 28
    Cesaroni G, Agabiti N, Forastiere F, Perucci CA. Socioeconomic differences in stroke incidence and prognosis under a universal healthcare system. Stroke 2009; 40: 28129.
  • 29
    Kirchmayer U, Di Martino M, Agabiti N et al. Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case-control study in Italy. Pharmacoepidemiol Drug Saf 2013; 22: 64957.
  • 30
    Pilz S, Henry RM, Snijder MB et al. Vitamin D deficiency and myocardial structure and function in older men and women: the Hoorn study. J Endocrinol Invest 2010; 33: 6127.
  • 31
    Murr C, Pilz S, Grammer TB et al. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med 2012; 50: 220512.
  • 32
    Semba RD, Houston DK, Bandinelli S et al. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur J Clin Nutr 2010; 64: 2039.
  • 33
    van Ballegooijen AJ, Visser M et al. Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab 2013; 98: 254452.
  • 34
    van Ballegooijen AJ, Visser M, Kestenbaum B et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol 2013; 111: 41824.
  • 35
    Kamycheva E, Wilsgaard T, Schirmer H, Jorde R. Serum 25-hydroxyvitamin D and left ventricular systolic function in a non-smoking population: the Tromsø Study. Eur J Heart Fail 2013; 15: 4905.
  • 36
    Ky B, Shults J, Keane MG et al. FGF23 modifies the relationship between vitamin D andcardiac remodeling. Circ Heart Fail 2013; 6: 81724.
  • 37
    Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011; 6: 28718.
  • 38
    Gutiérrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidneydisease. Circulation 2009; 119: 254552.
  • 39
    Kirkpantur A, Balci M, Gurbuz OA et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011; 26: 134654.
  • 40
    Udell JA, O'Donnell T, Morrow D et al. Association of fibroblast growth factor (FGF)-23 levels with risk of cardiovascular events in patients with stable coronary artery disease. J Am Coll Cardiol 2012; 59(13 Suppl.): E1480.
  • 41
    Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 6408.
  • 42
    Westerberg PA, Tivesten Å, Karlsson MK et al. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol 2013; 14: 85.
  • 43
    Wang L, Song Y, Manson JE et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012; 5: 81929.
  • 44
    Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 2012; 32: 2794802.
  • 45
    Dormuth CR, Hemmelgarn BR, Paterson JM et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013; 346: f880.
  • 46
    Krumholz HM, Lin Z, Keenan PS et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013; 309: 58793.
  • 47
    Agabiti N, Stafoggia M, Davoli M, Fusco D, Barone AP, Perucci CA. Thirty-day complications after laparoscopic or open cholecystectomy: a population-based cohort study in Italy. BMJ Open 2013; 3: e001943.
  • 48
    Kansagara D, Englander H, Salanitro A et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011; 306: 168898.
  • 49
    Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48: S11420.
  • 50
    Renzi C, Sorge C, Fusco D, Agabiti N, Davoli M, Perucci CA. Reporting of quality indicators and improvement in hospital performance: the P.Re.Val.E. Regional Outcome Evaluation Program. Health Serv Res 2012; 47: 1880901.